{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-014235","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2021-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.734336+00:00","generated_at":"2026-06-30T03:30:13.712385+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Champions Oncology reports record FY2021 revenue of $41M (+28% YoY); turns to operating profit of $338K","bullets":["FY2021 revenue $41.0M, up 28% from $32.1M; Q4 revenue $10.6M, up 21% from $8.8M.","Full-year operating income of $338K vs loss of $1.9M; Q4 operating loss narrowed to $456K from $2.0M.","Gross margin improved to 48% (FY2021) and 47% (Q4) vs 47% and 43% a year ago.","Cash position $4.7M with no debt; net cash used in ops $1.7M for the year.","Launched Lumin SaaS platform; developing AI/ML-driven target discovery using proprietary datasets."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-014235","json":"https://secwatch.observer/filing/0001628280-21-014235.json","markdown":"https://secwatch.observer/filing/0001628280-21-014235.md","text":"https://secwatch.observer/filing/0001628280-21-014235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828021014235/0001628280-21-014235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828021014235/csbr-20210722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T03:30:13.712385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}